Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1121-1140 of 2,120 trials

Plasmablastic Lymphoma: Daratumumab with Bortezomib and Dexamethasone

We are studying a combination of daratumumab, bortezomib, and dexamethasone for patients with relapsed or refractory plasmablastic lymphoma. The goal is to see if this treatment improves outcomes for those who cannot undergo stem cell transplantation.

Relapsed or Refractory Plasmablastic Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Prostate Cancer: PF-06821497 with Enzalutamide

We are studying a new treatment combining PF-06821497 with enzalutamide for men with advanced prostate cancer previously treated with abiraterone. The goal is to see if this combination can improve survival and reduce tumor activity compared to standard therapies.

Castration-resistant Prostate Cancer6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Myelodysplastic Syndrome: Targeted Treatment After Stem Cell Transplant

We are studying a new approach to prevent relapse and improve survival in patients with myelodysplastic syndrome after stem cell transplantation. The trial focuses on those with minimal residual disease to see if personalized treatment can help.

Myelodysplastic Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Solid Tumors: 68Ga-FAPI-46 PET-CT Imaging Study

We are testing a new imaging method to see if it can better identify issues in solid tumors when previous scans were unclear. This study aims to improve risk assessment and safety for patients with various tumor types.

Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Prostate Cancer: Radium-223 and Docetaxel Study

We are exploring whether using Radium-223 followed by Docetaxel helps men with bone-only metastatic prostate cancer feel better and live longer. This study will compare the effects of these treatments on quality of life and survival.

Metastatic Castration-Resistant Prostate CancerSymptomatic Bone-Only Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Long-term Safety of Genetically Modified T Cell Therapy

We are following up with patients who received genetically modified T cells to assess their long-term safety and survival. This study aims to understand how well the treatment works and any potential risks involved.

Acute Lymphoblastic LeukemiaSystemic Lupus ErythematosusNon-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncologyRheumatology

Multiple Sclerosis in Kids: Ofatumumab and Siponimod Study

We are comparing two new treatments, ofatumumab and siponimod, to fingolimod in children with multiple sclerosis. The study aims to see if these new options are as effective and safe for managing their condition.

Multiple Sclerosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Stage III Lung Cancer: Surgery and Durvalumab Study

We are exploring whether surgery is safe for patients with initially unresectable stage III lung cancer after high-dose treatment. We also want to see if they can benefit from a follow-up therapy called durvalumab.

Stage III Non-Small Cell Lung CancerMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Enterococcus faecalis Endocarditis: Continuous Infusion Antibiotics Study

We are studying whether continuous infusion of ampicillin and ceftriaxone is as effective as standard treatment for patients with Enterococcus faecalis infective endocarditis. This may help improve treatment outcomes and reduce complications.

Enterococcal Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Adnexal Torsion: Contrast-Enhanced Ultrasound Study

We are testing a new ultrasound method to see if it helps diagnose adnexal torsion more accurately than standard methods. This could reduce unnecessary surgeries and improve care for patients with suspected torsion.

Adnexal Torsion>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Semaglutide for Mood Improvement in Depression

We are studying if the medication semaglutide can help improve mood in people with major depressive disorder who are also overweight or obese. The trial will measure changes in depressive symptoms and overall well-being.

Unipolar DepressionObesity and Overweight6-12 monthsConfirmation phase (III)Monitoring phase (IV)Investigational MedicinesCost ReimbursementPsychiatry

Kidney Disease: Frexalimab, Brivekimig, and Rilzabrutinib Study

We are testing three new medications for people aged 16 to 75 with primary focal segmental glomerulosclerosis or minimal change disease. The goal is to see if they can reduce protein in urine and improve kidney function compared to a placebo.

Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease (MCD)Immune System Diseases1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Ovarian Cancer: Olaparib and Durvalumab Study

We are exploring whether Olaparib alone or with Durvalumab can be safely given to patients with high-grade ovarian cancer before surgery. This study may help us learn more about treatment effectiveness and safety.

Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Liver Fibrosis Assessment: 68Ga-FAPI Imaging Study

We are studying a new imaging technique to evaluate liver fibrosis in patients with suspected nonalcoholic steatohepatitis. This may help improve the accuracy of liver damage assessments compared to standard methods.

Non-Alcoholic Steatohepatitis (NASH)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyHepatologyInternal Medicine

Cardiogenic Shock: Beta Receptor Modulation Trial

We are testing a new approach to manage heart function in patients with cardiogenic shock on V-A ECMO. This study compares reducing beta receptor stimulation to the usual treatment to see which is safer and more effective.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Unresectable Malignant Mesothelioma: Tremelimumab Study

We are comparing a new treatment called tremelimumab to a placebo for patients with unresectable malignant mesothelioma. The goal is to see if it improves survival and overall health outcomes.

Malignant Mesothelioma>2 yearsEfficacy phase (II)Investigational MedicinesOncology

Cognitive Disorders: BioFINDER 2 Study

We are investigating new imaging methods to better diagnose Alzheimer's disease in healthy older adults and those with early cognitive symptoms. The goal is to understand brain changes that may lead to dementia.

Dementia and Neurodegenerative Disorders>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Relapsed Multiple Myeloma: Daratumumab Treatment Study

We are comparing two treatment strategies using Daratumumab, Lenalidomide, and Dexamethasone for patients with relapsed multiple myeloma. The goal is to see if a fixed treatment duration is as effective as continuous therapy.

Myeloma Recurrence>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Severe Infections in ICU: Comparing Antibiotics

We are studying whether piperacillin-tazobactam or temocillin can effectively treat severe infections caused by certain bacteria in ICU patients, compared to standard carbapenem treatment. This research may help improve treatment options for critically ill patients.

ESBL-Producing Bacteria Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Antisynthetase Syndrome: Cyclophosphamide vs Tacrolimus

We are comparing the effects of Cyclophosphamide and Azathioprine against Tacrolimus in patients with antisynthetase syndrome-related lung disease. The goal is to see which treatment better improves lung function and quality of life.

Interstitial Lung DiseaseConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology